Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction
- 1 January 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 41 (15), 1229-1245
- https://doi.org/10.2165/00003088-200241150-00001
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- TenecteplaseAmerican Journal of Cardiovascular Drugs, 2001
- Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial InfarctionThe Journal of Clinical Pharmacology, 2000
- Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarctionThe American Journal of Cardiology, 1999
- Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trialThe American Journal of Cardiology, 1999
- Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trialAmerican Heart Journal, 1999
- Current Clinical Use of Reteplase for ThrombolysisClinical Pharmacokinetics, 1999
- Simulation of Plasmatic Enzyme Reactions During Thrombolytic Therapy With Recombinant Tissue-Type Plasminogen Activator: from In Vitro Knowledge To New Assumptions In VivoSIMULATION, 1996
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionThe New England Journal of Medicine, 1993
- The Thrombolysis in Myocardial Infarction (TIMI) TrialThe New England Journal of Medicine, 1985
- Thrombolysis, clot selectivity, and kinetics.Circulation, 1984